Loading…
Satellos Bioscience Inc. is projected to rise to $13.93 by 2027, a +42% move from its current price of $9.79. MSLE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $9.32 | $9.80 | $10.30 | +0.06% |
| Jul 13 | $9.13 | $9.80 | $10.52 | +0.11% |
| Jul 14 | $8.99 | $9.81 | $10.69 | +0.17% |
| Jul 15 | $8.88 | $9.81 | $10.84 | +0.22% |
| Jul 16 | $8.78 | $9.82 | $10.98 | +0.28% |
| Jul 17 | $8.69 | $9.82 | $11.10 | +0.34% |
| Jul 18 | $8.61 | $9.83 | $11.22 | +0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.61 | $9.83 | $11.22 | +0.39% |
| Week 2 | $8.19 | $9.87 | $11.89 | +0.78% |
| Week 3 | $7.88 | $9.91 | $12.45 | +1.18% |
| Week 4 | $7.64 | $9.94 | $12.95 | +1.57% |
| Week 5 | $7.43 | $9.98 | $13.41 | +1.97% |
| Week 6 | $7.25 | $10.02 | $13.85 | +2.37% |
| Week 7 | $7.10 | $10.06 | $14.27 | +2.77% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Satellos Bioscience Inc. is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. Satellos has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc.
was founded in 2018 and is headquartered in Toronto, Canada.
Satellos Bioscience Inc. (MSLE) is currently trading at $9.79 per share with a market capitalization of $203.94M, and it ranks 3786 by market cap. The current price sits within a broad market context for a clinical-stage healthcare name. The near-term forecast shows a neutral path in 2026 with a min of $5.59, an avg of $9.79, and a max of $14.54.
A major floor 56.8% below — a decisive break under it would weaken the trend.
The nearest floor, 42.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 28.4% above — clearing it would confirm fresh momentum.
Key MSLE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MSLE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.94 | Buy | $9.01 | Buy |
| MA 10 | $8.24 | Buy | $8.33 | Buy |
| MA 20 | $7.05 | Buy | $7.62 | Buy |
| MA 50 | $7.06 | Buy | $7.27 | Buy |
| MA 100 | $7.82 | Buy | $7.41 | Buy |
| MA 200 | $7.50 | Buy | $7.29 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 76.29 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 152.82 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.36 | Buy |
| ROC (12) | 72.66 | Buy |
| Bollinger %B (20,2) | 1.01 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.65 | Buy |
| Awesome (5,34) | 2.07 | Buy |
| Ultimate (7,14,28) | 82.89 | Sell |
| Momentum (10) | 3.08 | Buy |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 9.64 | Buy |
| ADX (14) | 27.27 | Buy |
| ATR (14) | 0.35 | Info |
From 2027 onward, the forecast turns bullish with a rising trajectory. The 2027 forecast shows an avg of $13.93 and a max of $20.46 (ROI 42.3) while the 2028 forecast has an avg of $12.27 and a max of $19.14 (ROI 25.3). The 2029 forecast adds to the upside with an avg of $13.15 and a max of $21.49 (ROI 34.4), and the 2030 forecast continues the upward path with an avg of $14.73 and a max of $25.01 (ROI 50.5).
The sentiment across these years is predominantly BULLISH.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.59 | $9.79 | $14.54 | 0% | Neutral | |
| $10.24 | $13.93 | $20.46 | +42% | Bullish | |
| $8.53 | $12.27 | $19.14 | +25% | Bullish | |
| $8.71 | $13.15 | $21.49 | +34% | Bullish | |
| $9.35 | $14.73 | $25.01 | +50% | Bullish | |
| $8.63 | $14.16 | $24.85 | +45% | Bullish | |
| $12.10 | $20.62 | $37.26 | +111% | Bullish | |
| $13.45 | $23.76 | $44.09 | +143% | Bullish | |
| $12.37 | $22.64 | $43.02 | +131% | Bullish | |
| $12.57 | $23.82 | $46.27 | +143% | Bullish | |
| $16.03 | $35.62 | $75.78 | +264% | Bullish | |
| $35.07 | $77.93 | $179.24 | +696% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.59 | $9.79 | $11.59 | +0.00% |
| August 2026 | $7.91 | $9.55 | $11.99 | -2.43% |
| September 2026 | $8.42 | $10.30 | $13.19 | +7.84% |
| October 2026 | $8.54 | $10.56 | $13.74 | +2.53% |
| November 2026 | $8.32 | $10.39 | $13.71 | -1.60% |
| December 2026 | $8.64 | $10.89 | $14.54 | +4.80% |
Click any year to see its month-by-month MSLE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The MSLE price prediction for 2026 points to an average of $9.79 (low $5.59, high $14.54) — a potential gain of 0% on today's $9.79. Price action looks broadly range-bound.
In 2027, MSLE is projected to trade between $10.24 and $20.46, averaging $13.93 — a potential gain of +42% from today's $9.79. That is up +42% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Satellos Bioscience Inc.'s 2028 outlook centres on $12.27, within a $8.53 to $19.14 range. That is -12% versus the projected 2027 average. That marks a +25% change versus current levels. Momentum favours further upside here.
By 2029, MSLE could reach as high as $21.49, with a base case around $13.15 and support toward $8.71 — roughly +34% from $9.79. Buyers look set to stay in control over this stretch.
Expect MSLE to range from $9.35 to $25.01 through 2030. The $14.73 average target implies a +50% move from current prices. That is up +12% on the projected 2029 average. Momentum favours further upside here.
The MSLE price prediction for 2031 points to an average of $14.16 (low $8.63, high $24.85) — a potential gain of +45% on today's $9.79. Buyers look set to stay in control over this stretch.
In 2032, MSLE is projected to trade between $12.10 and $37.26, averaging $20.62 — a potential gain of +111% from today's $9.79. That is up +46% on the projected 2031 average. Momentum favours further upside here.
Satellos Bioscience Inc.'s 2033 outlook centres on $23.76, within a $13.45 to $44.09 range. That is up +15% on the projected 2032 average. That marks a +143% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, MSLE could reach as high as $43.02, with a base case around $22.64 and support toward $12.37 — roughly +131% from $9.79. Momentum favours further upside here.
Expect MSLE to range from $12.57 to $46.27 through 2035. The $23.82 average target implies a +143% move from current prices. That is up +5% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The MSLE price prediction for 2040 points to an average of $35.62 (low $16.03, high $75.78) — a potential gain of +264% on today's $9.79. Momentum favours further upside here.
In 2050, MSLE is projected to trade between $35.07 and $179.24, averaging $77.93 — a potential gain of +696% from today's $9.79. That is up +119% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in MSLE today (≈ 102.145046 MSLE) could be worth
$7,960.13
+$6,960.13 (+696%) by 2050 · US Dollar
Based on the average projected MSLE price of $77.93 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MSLEwould be worth at today's price.
$1,000 invested in MSLE on Jul 10, 2025 (≈ 201.775632 MSLE) would be worth
$1,975.38
+$975.38 (+97.5%) today · 1.98× · US Dollar
Based on a MSLE entry price of $4.96 vs. today's $9.79.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.42 | $1,319.41 | +31.9% |
| 1 month ago | $5.88 | $1,664.97 | +66.5% |
| 3 months ago | $6.5 | $1,506.15 | +50.6% |
| 6 months ago | $7.08 | $1,382.77 | +38.3% |
| 1 year ago | $4.96 | $1,975.38 | +97.5% |
| All time (5.0y) ago | $18.72 | $522.97 | -47.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MSLE forecast.
Our base-case forecast reaches $20.00 around 2032.
Implied market cap at $20.00: $416.62M
Looking further out, the multi-year forecast displays sustained upside with notable milestones. The 2040 forecast projects an avg of $35.62 and a max of $75.78 (ROI 263.8) with a BULLISH sentiment, and the 2050 forecast shows a striking avg of $77.93 and a max of $179.24 (ROI 696) while remaining categorized as BULLISH. The early view for 2026 remains neutral with an avg of $9.79 and ROI of 0, but the path from 2027 onward points to meaningful upside across the forecast horizon.
These figures illustrate potential growth under varying market conditions, but they are estimates, not guarantees, and are subject to uncertainty and risks inherent to clinical-stage drug development and equity markets.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $9.35, an avg of $14.73, and a max of $25.01, with an ROI of 50.5% and a bullish sentiment.
The forecast shifts to a BULLISH sentiment from 2027 onward, with a 2027 avg of $13.93 (ROI 42.3%), 2030 avg $14.73 (ROI 50.5%), 2040 avg $35.62 (ROI 263.8%), and 2050 avg $77.93 (ROI 696%). Note that 2026 is neutral with an avg of $9.79 and ROI of 0.
Yes. The 2030 forecast lists a max of $25.01, indicating the price could reach or exceed $25 in 2030.
The current price is $9.79 per share and the market capitalization is $203.94M.
Sentiment is NEUTRAL. RSI14 is 80, SMA50 is $7.06, SMA200 is $7.50. The 30-day range is $7.05 to $13.60, with near-term support at $5.62 and resistance at $9.79.
Satellos Bioscience Inc. Community Discussion
0Share your Satellos Bioscience Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.